Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment for skeletal metastases

01.07.2002


Norwegian and Swedish researchers have developed a new type of internal radiation therapy for cancer that has spread to skeletal tissue. Experience from an early patient test is optimistic, according to a report being presented at the 18th International Cancer Congress in Oslo this week.



Many patients with advanced breast, prostate or lung cancer experience metastasis to skeletal tissue. This is often a source of pain and suffering.

Exterior irradiation and medication, including radioactive substances injected into the bloodstream, can retard cancer growth in skeletal tissue, but now a new radium isotope may offer a new and better alternative. The first tests on Norwegian and Swedish patients are currently in progress, and the experience thus far gives grounds for optimism.


Isotopes are incorporated into skeletal tissue
Special cells called osteoclasts help build up skeletal tissue and try to help repair damaged tissue in areas affected by cancer. When small doses of the element radium are injected into the bloodstream, the osteoclasts will incorporate radium instead of calcium. This means radium can be incorporated into skeletal tissue, where it will give off radiation that kills cancer cells.

"Today, this type of ’internal’ radiation therapy is usually based on pharmaceuticals that contain strontium. Strontium has a scope of six to seven millimetres, meaning it can damage bone marrow and impair the production of new blood cells. But radium223 has a scope of just two millimetres. This leads us to believe that bone marrow will incur less damage", states Senior Medical Officer Lise Balteskard, PhD, University Hospital of Northern Norway. Along with physicians at the Norwegian Cancer Hospital, she has treated the first Norwegian patients with radium223.

The element radium is found in many isotope variants with different half-lives and scopes. The new isotope is a radium223 isotope developed at the Studsvik reactor in Sweden. In addition to the short scope of the radiation, it has a half-life of only 11 days.

Pain relief

In animal trials, this new isotope had good results on breast cancer that had spread to skeletal tissue. The animals lived longer and some were cured. (Cancer Research, June 2002). Experience from the first study on 20 Norwegian and Swedish patients indicates that many were able to use a lower dose of painkillers. This indicates that the treatment is effective.

"This is a phase 1 study where we are testing different doses to determine which dose we can administer without too many side effects. First and foremost, we are examining blood platelets and white cells in the blood to see whether their production is affected. The patients have advanced cancer. It was promising that many of them could take a lower dose of painkillers, as it implies improved quality of life. However, a phase 2 study is required to perform imaging, determine whether there is any reduction in malignant tissue, and systematically examine pain relief and survival", explains Balteskard.

"Is it possible that this new radium isotope might offer a cure for skeletal metastasis?"

"We believe this treatment might be administered the first time a tumour spreads to skeletal tissue, and that it might inhibit metastases. This would have an effect on pain and quality of life and could increase survival. It is still too early to tell whether such treatment might offer a cure if administered early enough", adds Balteskard.

Abstract P 459 in Poster Session 1 refers to the Norwegian-Swedish study on radium 223.
For more information, see the abstract from the symposium: Skeletal metastases, Monday, 08.45, inter alia in 15, Serafini, which will give an overview of bone-seeking radioactive isotopes for use in cancer treatment

Hanna Hånes | EurekAlert!
Further information:
http://www.kreft.no/

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Researchers devise microreactor to study formation of methane hydrate

23.08.2017 | Materials Sciences

ShAPEing the future of magnesium car parts

23.08.2017 | Automotive Engineering

New insights into the world of trypanosomes

23.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>